peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

GLP-1 + amylin combo

CagriSema

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

CagriSema is a once-weekly combination of cagrilintide and semaglutide.

Sources[2]pubmedEfficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.”

    Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. · BACKGROUND

    pubmed:42251860:a96d97c31ee6:a96d97c31ee6

Identity

CagriSema refers to a fixed-dose combination product containing cagrilintide plus semaglutide.

Sources[4]pubmedAmylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches.”

    Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo. · BACKGROUND

    pubmed:42583410:9222d3567edf:9222d3567edf

Identity

This statement defines what CagriSema contains, but provides no dosing ratio or amounts.

Sources[5]pubmedCo-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.CagriSema is a fixed-ratio combination of the long-acting GLP-1R agonist semaglutide and the calcitonin (CTR)/amylin receptor (AMYR) agonist cagrilintide
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “CagriSema is a fixed-ratio combination of the long-acting GLP-1R agonist semaglutide and the calcitonin (CTR)/amylin receptor (AMYR) agonist cagrilintide”

    Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding. · Abstract

    pubmed:42603595:7f55da893381:7f55da893381

How does it work?

Target, response, and disposition.

Mechanism

The abstract notes an evidence gap: the specific brain regions mediating potentiation with GLP-1R and CTR/AMYR co-agonism are not fully characterized.

Sources[5]pubmedCo-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.knowledge of the neural sites capable of producing potentiated effects as a result of GLP-1R/CTR/AMY co-agonism remains incomplete.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “knowledge of the neural sites capable of producing potentiated effects as a result of GLP-1R/CTR/AMY co-agonism remains incomplete.”

    Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding. · Abstract

    pubmed:42603595:7f55da893381:7f55da893381

What has been studied?

What the evidence says.

Comparative evidence

For the combined anthropometric endpoint at week 68, CagriSema showed a higher response proportion than semaglutide, cagrilintide, or placebo in this trial’s reported results.

Sources[3]pubmedEfficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.The proportion of participants achieving both BMI < 27 kg/m2and WHtR < 0.53 targets at week 68 was 30.3%, 19.1%, 9.0%, and 3.3% in participants who received CagriSema, semaglutide, cagrilintide, or placebo respectively.
Reported result
30.3% vs 19.1% vs 9.0% vs 3.3%
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The proportion of participants achieving both BMI < 27 kg/m2and WHtR < 0.53 targets at week 68 was 30.3%, 19.1%, 9.0%, and 3.3% in participants who received CagriSema, semaglutide, cagrilintide, or placebo respectively.”

    Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1. · RESULTS

    pubmed:42503495:3124217af3e1:3124217af3e1

Comparative evidence

This states the research objective, not results.

Sources[1]pubmedCagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.We aimed to investigate the efficacy and safety of a fixed-dose combination of cagrilintide and semaglutide (cagrilintide-semaglutide; known as CagriSema) versus semaglutide or cagrilintide for glycaemic control in people with type 2 diabetes and overweight or obesity.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “We aimed to investigate the efficacy and safety of a fixed-dose combination of cagrilintide and semaglutide (cagrilintide-semaglutide; known as CagriSema) versus semaglutide or cagrilintide for glycaemic control in people with type 2 diabetes and overweight or obesity.”

    Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. · BACKGROUND

    pubmed:42251859:60caba6bb84f:60caba6bb84f

Study findings

By week 68, 30.3% of CagriSema-treated participants met the combined anthropometric targets BMI < 27 kg/m2 and WHtR < 0.53.

Sources[3]pubmedEfficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.The proportion of participants achieving both BMI < 27 kg/m2and WHtR < 0.53 targets at week 68 was 30.3%, 19.1%, 9.0%, and 3.3% in participants who received CagriSema, semaglutide, cagrilintide, or placebo respectively.
Reported result
30.3%
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The proportion of participants achieving both BMI < 27 kg/m2and WHtR < 0.53 targets at week 68 was 30.3%, 19.1%, 9.0%, and 3.3% in participants who received CagriSema, semaglutide, cagrilintide, or placebo respectively.”

    Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1. · RESULTS

    pubmed:42503495:3124217af3e1:3124217af3e1

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, interaction, regulatory, safety
  • 165 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (101), assurance_score_below_0.72 (54), current_regulatory_source_required (20), extraction_ambiguity (94), high_risk_requires_regulatory_or_two_independent_sources (60), no_direct_support (155), proposal_not_staged (3)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. ↗

    pubmed · published 2026-08-01 · retrieved 2026-08-21T08:29:16Z

  2. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. ↗

    pubmed · published 2026-08-01 · retrieved 2026-08-21T08:29:16Z

  3. Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1. ↗

    pubmed · published 2026-07-26 · retrieved 2026-08-25T22:58:23Z

  4. Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo. ↗

    pubmed · published 2026-08-01 · retrieved 2026-08-19T08:29:05Z

  5. Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding. ↗

    pubmed · published 2026-08-15 · retrieved 2026-08-21T08:29:16Z

Publication history and provenance

Version 7 · Automated assessment · 2026-08-28T12:09:49Z

36305a84163d1a416a52e462e7abf08b559e06fd2c099a56af6fd619b1ba39f7